New therapies poised to transform complement 3 glomerulopathy market
The market for complement 3 glomerulopathy (C3G) treatments is set for significant change with the upcoming launch of several novel therapies. These advancements aim to address unmet needs in C3G management.
The treatment landscape for complement 3 glomerulopathy (C3G) is evolving with the introduction of new, targeted therapies. Historically, C3G treatment relied heavily on the off-label use of existing medications, highlighting a substantial unmet need for disease-specific options.
The landscape began shifting with the approval of FABHALTA, the first drug specifically indicated for C3G, followed by EMPAVELI/ASPAVELI from Apellis Pharmaceuticals and Sobi. However, both therapies carry boxed warnings for serious infections, necessitating vaccination prior to treatment.
Several new therapies are now emerging, targeting novel mechanisms of action. These include dual complement inhibitors (KP104), MASP-3 inhibitors (Zaltenibart), and RNA interference (RNAi) therapeutics targeting complement C3 (ARO-C3).
The C3G market across seven major regions was valued at approximately USD 1 billion in 2025. Projections indicate robust growth with an anticipated compound annual growth rate of 28% by 2036, reflecting significant clinical and commercial interest.